These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Human Leukocyte Antigen Class I Antibodies and Response to Platelet Transfusion in Patients Undergoing Liver Transplantation. Wong M; Narra R; Selim M; Zimmerman MA; Kim J; Padmanabhan A; Hong JC J Surg Res; 2020 Nov; 255():99-105. PubMed ID: 32543385 [TBL] [Abstract][Full Text] [Related]
3. Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim. Krečak I; Skorić I; Čengić M; Krečak F; Skelin M Transfus Apher Sci; 2023 Apr; 62(2):103582. PubMed ID: 36253251 [TBL] [Abstract][Full Text] [Related]
4. Prognostic Significance of Platelet Recovery in Myelodysplastic Syndromes With Severe Thrombocytopenia. Tang Y; Zhang X; Han S; Chu T; Qi J; Wang H; Tang X; Qiu H; Fu C; Ruan C; Wu D; Han Y Clin Appl Thromb Hemost; 2018 Dec; 24(9_suppl):217S-222S. PubMed ID: 30296835 [TBL] [Abstract][Full Text] [Related]
5. Transfusion-induced alloimmunization and platelet refractoriness in a mouse model: mechanisms and interventions. Waterman HR; Kapp LM; Munday A; Odem-Davis K; Zimring JC Transfusion; 2016 Jan; 56(1):91-100. PubMed ID: 26400622 [TBL] [Abstract][Full Text] [Related]
6. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study. Sintnicolaas K; van Marwijk Kooij M; van Prooijen HC; van Dijk BA; van Putten WL; Claas FH; Novotny VM; Brand A Blood; 1995 Feb; 85(3):824-8. PubMed ID: 7833483 [TBL] [Abstract][Full Text] [Related]
7. Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients. Jia Y; Li W; Liu N; Zhang K; Gong Z; Li D; Wang L; Wang D; Jing Y; Wang J; Shan X Transfus Med; 2014 Dec; 24(6):406-10. PubMed ID: 25327352 [TBL] [Abstract][Full Text] [Related]
8. Human Leukocyte Antigen Alloimmunization and Alloimmune Platelet Refractoriness. Saris A; Pavenski K Transfus Med Rev; 2020 Oct; 34(4):250-257. PubMed ID: 33127210 [TBL] [Abstract][Full Text] [Related]
10. Reduced alloimmunization in mice following repeated transfusion with pathogen-reduced platelets. Muench MO; Heitman JW; Inglis H; Fomin ME; Marschner S; Goodrich RP; Norris PJ; Jackman RP Transfusion; 2016 Jun; 56(6):1419-29. PubMed ID: 27028210 [TBL] [Abstract][Full Text] [Related]
11. Use of platelet transfusions and tranexamic acid in patients with myelodysplastic syndromes: A clinical practice survey. Mo A; Weinkove R; Wood EM; Shortt J; Johnston A; McQuilten ZK; Eur J Haematol; 2024 Apr; 112(4):621-626. PubMed ID: 38123137 [TBL] [Abstract][Full Text] [Related]
12. Platelet transfusion refractoriness due to HLA alloimmunization: Evolving paradigms in mechanisms and management. Panch SR; Guo L; Vassallo R Blood Rev; 2023 Nov; 62():101135. PubMed ID: 37805287 [TBL] [Abstract][Full Text] [Related]
13. Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes. Mo A; Wood E; Shortt J; Hu E; McQuilten Z Eur J Haematol; 2023 Oct; 111(4):592-600. PubMed ID: 37452616 [TBL] [Abstract][Full Text] [Related]
15. Longitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes (CME). Wiita AP; Nambiar A Transfusion; 2012 Oct; 52(10):2146-54. PubMed ID: 23113654 [TBL] [Abstract][Full Text] [Related]
16. The association and functional relevance of genetic variation in low-to-medium-affinity Fc-gamma receptors with clinical platelet transfusion refractoriness. Nagelkerke SQ; Porcelijn L; Geissler J; Tanck MWT; Huiskes E; van Bruggen R; van den Berg TK; de Haas M; Kuijpers TW J Thromb Haemost; 2020 Aug; 18(8):2047-2053. PubMed ID: 32588549 [TBL] [Abstract][Full Text] [Related]
17. Successful use of rituximab in platelet transfusion refractoriness in a multi-transfused patient with myelodysplastic syndrome. Yu QH; Shen YP; Ye BD; Zhou YH Platelets; 2015; 26(2):195-6. PubMed ID: 23634876 [TBL] [Abstract][Full Text] [Related]
18. Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS). Oliva EN; Riva M; Niscola P; Santini V; Breccia M; Giai V; Poloni A; Patriarca A; Crisà E; Capodanno I; Salutari P; Reda G; Cascavilla N; Ferrero D; Guarini A; Tripepi G; Iannì G; Russo E; Castelli A; Fattizzo B; Beltrami G; Bocchia M; Molteni A; Fenaux P; Germing U; Ricco A; Palumbo GA; Impera S; Di Renzo N; Rivellini F; Buccisano F; Stamatoullas-Bastard A; Liberati AM; Candoni A; Delfino IM; Arcadi MT; Cufari P; Rizzo L; Bova I; D'Errigo MG; Zini G; Latagliata R J Clin Oncol; 2023 Oct; 41(28):4486-4496. PubMed ID: 37294914 [TBL] [Abstract][Full Text] [Related]
19. Somatic mutations show no clear association with red blood cell or human leukocyte antigen alloimmunization in de novo or therapy-related myelodysplastic syndrome. Adkins BD; Mehta A; Selesky M; Vittitow S; Smolkin ME; Ratcliffe SJ; Luckey CJ Transfusion; 2022 Dec; 62(12):2470-2479. PubMed ID: 36278434 [TBL] [Abstract][Full Text] [Related]